Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
REtroperitoneal SArcoma Registry: an International Prospective Initiative
NCT03838718 · View on ClinicalTrials.gov ↗
Study Summary
Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority. Primary Objectives of this study are: * to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. * patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM). Secondary Objectives: * to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; * to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy; * to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease; * to utilize collected pathological material for research collaborations.
Conditions Studied
Study Locations (20)
Other
- Peter MacCallum Cancer Center — Melbourne
- Maisonneuve-Rosemont Hospital / University of Montreal — Montreal
- The Ottawa Hospital — Ottawa
- Mount Sinai / Princess Margaret — Toronto
- Institut Curie — Paris
- University Medical Center and Medical Faculty Mannheim, University of Heidelberg — Mannheim
- Ludwig Maximilian University — Munich
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan
- Veneto Institute of Oncology — Padua
- Ospedale Borgo Roma — Verona
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology — Warsaw
- Institute of Oncology Ljubljana — Ljubljana
- Samsung Medical Center — Seoul
- Hospital Clinico Universitario "Virgen de la Arrixaca" — Murcia
Florida
- Mayo Clinic — Jacksonville
- Moffitt Cancer Center — Tampa
California
- University of Southern California (USC) — Los Angeles
Georgia
- Winship Cancer Institute — Emory
Massachusetts
- Brigham and Women's Hospital/Dana-Farber Cancer Institute — Boston
Ohio
- The Ohio State University — Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2030-12-31 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03838718
The ClinicalTrials.gov registry entry for NCT03838718 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Retroperitoneal Sarcoma appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03838718 reports 20 study locations spanning 6 distinct geographic areas — top geographies include Other, Florida, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03838718 about?
NCT03838718 is a clinical study titled "REtroperitoneal SArcoma Registry: an International Prospective Initiative". Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a to...
What is the current status of trial NCT03838718?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2016-09-01. Estimated completion is 2030-12-31.
What conditions does trial NCT03838718 study?
This clinical trial studies the following conditions: Retroperitoneal Sarcoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT03838718?
This trial is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03838718 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.